CA2138975C

CA2138975C - Topical application composition

Info

Publication number: CA2138975C
Application number: CA002138975A
Authority: CA
Inventors: Udo Gross; Joachim Roding; Klaus Stanzl; Leonhard Zastrow
Original assignee: Lancaster Group AG
Current assignee: Lancaster Group AG
Priority date: 1992-06-26
Filing date: 1993-06-24
Publication date: 2003-05-13
Anticipated expiration: 2013-06-24
Also published as: IL105947A0; PL172360B1; DE59301120D1; HK1002701A1; JPH07508007A; SK279823B6; CA2138975A1; AU671645B2; GR3018337T3; HUT68858A; FI946057A; DK0647129T3; FI946057A0; ES2083871T3; NO303666B1; EP0647129A1; IL105947A; AU4307993A; CZ326894A3; ATE131031T1

Abstract

The invention relates to a preparation for topical use, having light protection properties and in a special application form. In the known light protection agents containing the naturally occurring active compound melanin, the problem is inadequate transport of the melanin to its site of action. According to the inven-tion, this problem is solved by a preparation for topical use which is characterised in that it contains melanin, dissolved or dispersed in one or more fluorocarbons, which are present as asymmetric lamellar phospholipid aggregates in an aqueous system together with a phospholipid, with a particle size of the aggregates in the range from 200 to 3000 nm.

Description

,~
~1 ~89'7~
P A T E N T A N W A L T E Hans-~urgen Fell~e Patent Attorney FELKE & WALTER Wolf-Jiirgen Walter Patent Attorney EUROPEAN PATENT ATTORNEYS Am Stadtpar D-1156 n Telep : (00372)5590981 efax~ (00372)5592508 Preparation for topical use The invention relates to a cosmetic or dermatological composition having light protection properties in a special application form, in which fluorocarbon-containing asymmetric lamellar phospholipid aggregates function as carriers of melanin.
It is known that short-wave W light (UV/A, W/B;
UV/C, wavelength ranges from 400 to 200 nm) can have a damaging effect on the skin and is a significant factor for premature skin ageing. In extreme form, the action can consist in a cytogenetic change in individual skin cells and lead to the formation of skin carcinomas (melanomas). These hazards have continuously increased due to environmentally related factors (ozone hole) with an increased W burden. In order to overcome this fact, it is customary, by means of special cosmetics and dermatological agents, to protect the exposed skin tissue by the use of special W light protection filters. The active compound of these compositions is based on the following principles:
1. Absorption of W light by the use of W-active organic compounds 2. Scattering of W light by finely dispersed tita nium dioxide or other micropigments The efficacy of these systems, which can be detected simply by recording their W absorption maxima in the wavelength range 250-400 nm or by scattering curves, is evident. The problem, however, is the biologi-cal acceptability of the substances, in particular the possible chemical substance alterations under the ' ~ 1 ~~ ~~'?~

influence of energy-rich radiation.
A further critical point is the depth of penetra-tion of the W filter into the skin when it is used as a constituent of a cosmetic or dermatological agent. The suitable site of action is the region between the horny layer and basal layer. In order to meet these demands, testing for one year is necessary, as has been previously prescribed for pharmacological active compounds. Accor-ding to their intended use and their individual efficacy, the W filters are applied topically in a suitable medium in a wide concentration range between 1 and 10 %.
Thus, e.g., DE-A-3242385 (Zabotto) describes a cosmetic composition which, in addition to other active compounds, contains 1.5 % Parsol Ultra (Givaudan) for the reduction of skin ageing due to the action of light.
Melanin, which also occurs in human and animal cells, the melanocytes, is known as a natural light protection active compound in higher organisms. Melanin is a brown to black-coloured polymeric pigment of the vertebrates, which is formed, inter alia, from the amino acid tyrosine and pigments both skin, hair and iris. The melanin formed in the melanocytes of the skin migrates into the basal layer of the epidermis and there releases the pigment into the epidermal cells. Since melanin, as a polymeric substance, hardly dissolves, the previous attempts to bring this substance to its site of action by means of topical applications are to be regarded as not thoroughly successful.
The invention has set the object of making possible topical use of melanin at its site of action.
According to the invention, a preparation for topical use having light protection properties is characterised in that it contains melanin which is dissolved or dispersed in one or more lipophilic fluoro-carbons which are present as asymmetric lamellar phospholipid aggregates in an aqueous system together with a phospholipid, with a particle size of the aggre-gates in the range from 200 to 3000 nm.
The naturally obtained (e. g. from Sepia ~.~ 389' 5 ~- _ officinalis) or synthetically produced (oxidation of tyrosine, e.g. with HzOz) melanin is present, dissolved or suspended by the fluorocarbon, encapsulated in the core of the asymmetric lamellar phospholipid aggregates. The structural arrangement in the lamellar aggregates is fundamentally different from that of aqueous liposomes (vesicles). The hydrophobic nature of the fluorocarbon calls for a reversal in the polarity of the phospholipid molecule such that the lipophilic fatty acid radicals interact with the fluorocarbon in the core of the aggre-gate by dispersive forces. In this arrangement, further phospholipid bilayer films are constructed to give asym-metric lamellar globular aggregates according to spec-ified conditions.
The novel asymmetric structure was confirmed by Sip-NMR investigations and spectroscopic investigations.
The exceptional stability of the aggregates results from their lamellar structure and from the corresponding surface charge .
A plurality of fluorocarbons can be employed, e.g. aliphatic straight-chain and branched fluoroalkanes, mono- or bicyclic and optionally fluoroalkyl-substituted fluorocycloalkanes, perfluorinated aliphatic or bicyclic amines, bis(perfluoroalkyl)ethenes, perfluoropolyethers and mixtures thereof. Particularly preferred fluoro-carbons are those such as perfluorodecalin, F-butyltetra-hydrofuran, perfluorotributylamine, perfluorooctyl bromide, bis-fluoro(butyl)ethene or bis-fluoro(hexyl)-ethene or C6-C9-perf luoroalkanes . The amount of f luoro-carbons here is in the range from 20 to 100 o w/v, preferably in the range from 40 to 100 a. A particularly preferred range is that from 70 to 100 a w/v.
It was possible to determine the dependence of the penetration rate and the depth of penetration on the particle size of the aggregates experimentally by separ ate investigations using labelled encapsulated fluoro-carbons. According to these experiments, smaller par-ticles migrate more rapidly and more deeply into the skin tissue than larger particles. The choice of fluorocarbons ~~~~~?5 ' '- _ 4 _ or their mixtures according to their lipid solubility (represented by their critical solubility temperature CST
in n-hexane) allows, as a further important criterion, the regulation of the residence time in the tissue.
While, e.g. perfluorotributylamine (F-TBA, CST 59°C)~
having a high CST value and poor lipid solubility has a relatively high residence time, in contrast to this perfluorodecalin (PFD, CST 22°C) but also F-butyltetra-hydrofuran, F-hexane and others are released correspondingly more rapidly from the tissue. With the aid of fluorocarbon mixtures, systems with desired CST
values, i.e. lipid and membrane solubilities, can be prepared specifically with respect to the intended use.
The content of the fluorocarbons in the lamellar.
aggregates can vary between 1 and 100 ~S w/v according to the intended use. Suitable fluorocarbons are in particular:
aliphatic straight-chain and branched alkanes having 6 to 12 carbon atoms, e.g. perfluorohexane, perfluorooctane, perfluorononane;
mono- or bicyclic cycloalkanes, which are optionally F-alkyl-substituted, e.g. perfluoromethylcyclohexane, perfluorodecalin;
aliphatic tertiary amines, N-containing polycycles, e.g.
perfluorotripopylamine [sic), perfluorotributylamine, F-cyclohexylmethylmorpholine;
perfluoroethers, such as aliphatic ethers, F-alkylfurans, bicyclic and substituted bicyclic ethers having two or three oxygen atoms in the molecule, e.g. perfluorodihexyl ether, perfluorobutyltetrahydrofuran, perfluoropoly-ethers;
perfluoroalkyl halides, e.g. perfluorooctyl bromide, perfluorohexyl bromide, perfluorooctyl chloride;
Bis-F(alkyl)ethenes, e.g. bis-F(butyl)ethene, bis-F(hexyl)ethene.
The term "fluorocarbons" used here is understood as meaning perfluorinated or highly fluorinated carbon compounds or mixtures which are able to transport gases such as OZ and CO2. Partially fluorinated hydrocarbon ~1~~9'~~
_ 5 _ compounds within the context of this invention are those in which most of the hydrogen atoms are replaced by fluorine atoms, e.g. the bis-F(alkyl)ethenes which, as far as can be detected, are chemically and biologically inert and thus non-toxic. This is usually achieved when approximately up to 90 % of the hydrogen atoms are replaced by fluorine atoms. Preferred fluorocarbons within the context of the present invention are those in which at least 95 % of the hydrogen atoms are replaced, more preferably 98 % and most preferably 100 %.
Suitable phospholipids are naturally occurring phospholipids such as Soya or egg lecithin, and also lecithins (phospholipids) which can be prepared syntheti-cally and which overall are known as being skin-com-patible and good for the skin. Because of the advantageous action on the stability of the asymmetric lamellar aggregates, phospholipid mixtures having a content from 10 to 99 %, preferably 30 to 99 %, in particular 60 to 90 % of phosphatidylcholine in addition to other naturally occurring accompanying products are preferably used. The phospholipid content in the topical formulation varies between 0.5 and 20 %, preferably 10 to 20 %.
The particle sizes of the aggregates, and the phospholipids are selected such that a penetration into deeper layers of the skin, e.g. into the epidermis or the dermal region does not take place and the light protec tion filter according to the invention thus reaches its site of action after it has penetrated the horny layer.
The particle sizes are in the range from 200 to 3000 nm, preferably in the range from 250 to 1000 nm.
The invention also relates to a process for the production of preparations for topical use, which is characterised in that melanin is dissolved or dispersed in one or more fluorocarbons and this dispersion is converted by homogenisation with a phospholipid in an aqueous system into' asymmetric lamellar phospholipid aggregates containing the fluorocarbons and melanin, having particle sizes between 200 and 3000 nm.

~.i~~9~~
-- _ The solubility of the polymeric melanin can be increased by addition of lipophilic substances to the fluorocarbon as solubilisers. Suitable lipophilic sub-stances are native oils, triglycerides or aliphatic alkanes, selected from the group consisting of olive oil, soya bean oil, sunflower oil, pentane, heptane, nonane, decane or mixtures thereof.
The homogenisation can be effected by customary processes, e.g. using a high-speed stirrer (12,000 to 15,000 rpm), by ultrasound or by means of pressure homogenisation such that the particle size is ensured.
The invention will be illustrated in greater detail below by means of examples. In the associated drawings Fig. 1 is a diagram of the critical solubility tempera-tures (CST) of perfluorocarbon mixtures in n-hexane using perfluorodecalin as a starting point Fig. 2 is a diagram of the critical solubility tempera tures of perfluorocarbon mixtures in n-hexane using F-octylbromide as a starting point.
Some selected fluorocarbons and their OZ solubi-lity, their vapour pressure and their critical solubility temperature are shown in Table 1. Starting from these values, the desired characteristics for the penetration of the skin with the aid of the composition according to the invention can be selected for mixtures of fluoro-carbons.
Table 1 Fluorocarbon Oz solubility Vapour CST
[m] [sic] of Pressure Oz~100 ml of Fc] P37e~
[mm Hg]
Perfluorooctyl bromide 50 14 -24.5 Perfluorodecalin 40 12.5 22 bis-F(butyl)ethene ~ 50 12.6 22.5 F-cyclohexylmethyl-morpholine 42 4 38.5 F-tripropylamine 45 18.5 43 ~.13~9?~
_ 7 _ F-dihexyl ether 45 2 59 F-tributylamine 40 1 59 Perfluorodecalin-F-tributylamine 1:1 40 7 42 Perfluorobutyl-tetrahydrofuran 52 51 29 F-methylcyclohexane 57 180 8.2 F-hexane 58 414 20 Example 1 A 10 % strength aqueous phospholipid solution of soya lecithin and containing 40 a phosphatidylcholine was mixed with cooling in an ultrasonic disintegrator with a fluorocarbon mixture composed of perfluorodecalin (90 %) and F-dibutylmethylamine (10 %) and melanin. The asym-metric lamellar phospholipid aggregates obtained in this process had a mean particle size of approximately 240 nm and contained the melanin.
The aggregates prepared in this manner were incorporated into the following processing forms of light protection agents according to customary processes.
Example 2 Emulsion (body lotion) Polyacrylic acid 0.30 TEA 0.30 %

p-Methylhydroxybenzoate 0.20 p-Propylhydroxybenzoate 0.10 %

Imidazolidinylurea 0.20 %

Na EDTA 0.06 %

Cetyl/stearyl alcohol, 1.00 %

Stearic acid 1.00 %

Isopropyl myristate/palmitate 3.00 Liquid paraffin 4.00 %

Jojoba oil 2.00 %

Melanin/phospholipid aggregates 10.00 Perfume oil 1.00 Demineralised water q~s~

_ g _ Example 6 sic] Emulsion (cream) Polyacrylic acid 0.30 Propylene glycol 5.00 TEA 0.30 Emulsifier 1 6.00 %

Emulsifier 2 4.50 %

Aloe vera 2.00 Rice husk oil 1.50 %

Cetyl/stearyl alcohol 1.00 Jojoba oil 1.50 %

p-Methylhydroxybenzoate 0.20 p-Propylhydroxybenzoate 0.10 %

Imidazolidinylurea 0.20 %

Melanin/phospholipid aggregates 20.00 Perfume oil 1.00 Demineralised water q.s.

ExamQle 4 Lotion Emulsifier system consisting of water, 34.00 stabilisers, polyglycerol esters, polyoxyethylene esters, isopropyl palmitate Glycerol 5.00 2 MgS04 . 7H20 0 . 5 0 Melanin/phospholipid aggregates 6.00 %

p-Methylhydroxybenzoate 0.20 %

p-Propylhydroxybenzoate 0.10 Imidazolidinylurea 0.30 Perfume oil 1.00 Demineralised water q~s~

Example 5 Eyeshadow compressed with licrht protection factor Talc 40.00 Mg carbonate , 1.50 %

Mg stearate 2.50 %

Kaolin 2.20 Colorants 15.80 %

~.~~~9°~~
"' - 9 -Pearl lustre pigments 21.50 a Perfume oil 1.50 Silk protein 5.00 Emulsion as processing means Emulsifier 4.50 Silicone oil, volatile 2.50 0 Melanin/phospholipid aggregates 4.50 0 Preservative 0.30 Demineralised water q.s.

Claims

1. ~A preparation for topical use, comprising melanin, dissolved or dispersed in one or more fluorocarbons, which are present as asymmetric lamellar phospholipid aggregates in an aqueous system together with a phospholipid, with a particle size of the aggregates in the range from 200 to 3000 nm.

2. ~A preparation according to claim 1, characterized in that the amount of fluorocarbons is in the range from 1 to 100% w/v.

3. ~A preparation according to claim 1 or 2, wherein the fluorocarbons are selected from the group consisting of aliphatic straight-chain and branched fluoroalkanes, mono- or bicyclic, optionally fluoroalkyl-substituted, fluorocycloalkanes, per-fluorinated ali-phatic or bicyclic amines, bis(perfluoroalkyl)ethenes, perfluoropolyethers and mixtures thereof.

4. ~A preparation according to claim 3, wherein the fluorocarbons are selected from the group which consists of perfluorodecalin, F-butyltetrahydrofuran, perfluoro-tributylamine, perfluorooctyl bromide, bis-fluoro-(butyl)ethene and C6-C9-peerfluoroalkanes.

5. ~A preparation according to claim 1, 2, 3 or 4, wherein the amount of fluorocarbons is in the range from 20 to 100% weight/volume.

6. A preparation according to claim 5, wherein said amount is in the range from 40 to 100%
weight/volume.

7. A preparation according to claim 5, wherein said amount is in the range from 70 to 100%
weight/volume.

8. A preparation according to any one of claims 1 to 7, wherein said one or more fluorocarbons have a critical solubility temperature below 50°C.

9. A preparation according to claim 8, wherein said critical solubility temperature is below 30°C.

10. A preparation according to any one of claims 1 to 9, wherein the phospholipid is selected from the group consisting of natural phospholipids, synthetic phospholipids and hydrogenated lecithins and partially hydrogenated phospholipids.

11. A preparation according to any one of claims 1 to 9, wherein the phospholipid is soya lecithin or egg lecithin.

12. A preparation according to any one of claims 1 to 11, wherein said asymmetric lamellar phospholipid aggregates comprise a central core of fluorocarbons surrounded by layers of phospholipid molecules wherein a layer adjacent to said central core has the lipophilic moiety of the phospholipid interact with the fluoro-carbon.

13. A preparation according to any one of claims 1 to 12, wherein phosphatidylcholine is present in an amount from 10 to 99% by weight.

14. A preparation according to claim 13, wherein said phosphatidylcholine is present in an amount of 30 to 99%, by weight.

15. A preparation according to claim 13, wherein said phosphatidylcholine is present in an amount of 70 to 90%, by weight.

16. A preparation according to claim 12, 13, 14 or 15, which contain lysolecithins in a concentration range from 1 to 10% by weight.

17. A preparation according to any one of claims 1 to 16, further including a solubiliser, selected from the group consisting of:
i) native oils;
ii) triglycerides;
iii) aliphatic alkanes; and iv) mixture within i), ii) and iii) or between i), ii) and iii).

18. A preparation according to claim 17, wherein said native oils axe selected from olive oil, soya bean oil and sunflower oil, and said alkanes are selected from pentane, heptane, nonane and decane.

19. A process for the production of a preparation for topical use comprising dissolving or dispersing in one or more fluorocarbons and homogenising with a phospholipid in an aqueous system into asymmetric lamellar phospholipid aggregates containing the fluorocarbons and melanin, having particle sizes between 200 and 3000 nm.

20. A process according to claim 19, wherein a solubiliser, selected from the group consisting of:
i) native oils;
ii) triglycerides;
iii) aliphatic alkanes; and iv) mixtures within or between i), ii) and iii), is added to melanin and the fluorocarbons.

21. A process according to claim 20, wherein said native oils are selected from olive oil, soya bean oil and sunflower oil, and said alkanes are selected from pentane, heptane, nonane and decane.

22. Use of asymmetric lamellar phospholipid aggregates for introducing melanin into the skin region above the epidermis, the asymmetric lamellar phospholipid aggregates consisting of a phospholipid and one or more fluorocarbons containing melanin dissolved or dispersed therein, the particle size of the aggregates being in the range from 200 to 3000 nm.

23. ~Use according to claim 22, wherein said aggregates have a phosphatidylcholine content of the phospholipids from 10 to 99% by weight.

24. ~Use according to claim 23, wherein said content is 30 to 99%, by weight.

25. ~Use according to claim 23, wherein said content is 70 to 90%, by weight.